Join

Compare · ACST vs HUGE

ACST vs HUGE

Side-by-side comparison of Acasti Pharma Inc. (ACST) and FSD Pharma Inc. (HUGE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACST and HUGE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • HUGE is the larger of the two at $55.5M, about 1.1x ACST ($49.6M).
  • ACST has more recent analyst coverage (2 ratings vs 0 for HUGE).
MetricACSTHUGE
Company
Acasti Pharma Inc.
FSD Pharma Inc.
Price
$3.59+9.79%
$0.09-8.17%
Market cap
$49.6M
$55.5M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
0
0
Recent ratings
2
0
ACST

Acasti Pharma Inc.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia; and TRILOGY that is in Phase III to evaluate the safety and efficacy of CaPre in patients with sHTG. The company was incorporated in 2002 and is headquartered in Laval, Canada.

HUGE

FSD Pharma Inc.

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.

Latest ACST

Latest HUGE